Plain-language summary

This Phase 2 trial is testing UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis and THERAKOS® CELLEX photopheresis system for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis (DRUG): Extracorporeal Photopheresis (ECP) | THERAKOS® CELLEX photopheresis system (DEVICE): THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system

Drugs / treatments

UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details